By Dr. C M Batra, Endocrinology
In spite of being a very common disease, every patient of diabetes has a unique method of treatment. In the rarest of cases, if the condition is not treated, it can result in a large number of complicated situations. Usual treatments include maintenance of a healthy diet and nutritious habits. The latest development in the field of the treatment of diabetes is the introduction of the first and only weekly medication called Trulicity, which becomes a part of a rare class of injections which further allow the user to manage the blood sugar levels of type-2 diabetes.
A majority of the human population suffering from diabetes exhibit the type-2 variety. This causes high sugar levels which in turn results in health problems like vision problems, heart diseases and nerve and kidney damage.
Trulicity (common name Dulaglutide) is a kind of medication called glucagon-like peptide-1 (GLP-1) receptor agonist. Initial tests were conducted by the FDA (US Food and Drug Administration), involving around 3500 subjects having type-2 diabetes. Individual as well as combinational tests using other diabetic drugs were performed. A marked improvement in long term blood sugar levels was noted in patients who were given weekly dosage of the drugs. It is not used alone but in a combination with metformin and sulphonylureas as a 2nd or 3rd line drug.
Common side effects of usage of this drug included vomiting, nausea, diarrhea, reduction in appetite and abdominal pain. Trucility is not advised for patients who exhibit a family history of any form of thyroid cancer or for patients who have tumors in different glands in the body. It is not prescribed for people with type-1 diabetes or even as the first treatment for type-2 patients.